📡 AI Distillation ── 2026-06-27

Key points for using generative AI (LLMs) in pharmaceutical and promotional materials review (checking marketing materials for compliance with the Pharmaceutical and Medical Device Act and the Standards for Proper Advertising of Drugs, etc.). **Benefits** - Accelerates initial screening of large volumes of materials. Comprehensive primary extraction of misleading advertising (Act Article 66), unapproved indications (Article 68), and consistency issues (discrepancies with package inserts). - Reduces inter-reviewer variation; explanations citing relevant statutes and guidelines (JPMA Promotion Code, Standards for Proper Advertising — notice from the Director of the Office of Pharmaceutical Safety) have an educational effect. **Risks** - Hallucination (fabrication of nonexistent article numbers or case law). Misidentification of articles (Articles 66/68/68-2). - Training data becoming stale, preventing reflection of the latest notices and revisions. Final responsibility for judgments rests with humans (review staff, regulatory affairs). - Information leakage from sending confidential materials or personal data to external APIs; GxP/CSV and audit trail requirements. **Implementation considerations** - Use a RAG architecture grounded in primary sources (package inserts, original notices), with mandatory citation of sources in all outputs. Limit LLM role to "flagging candidates for review"; approval/rejection decisions are made by humans (human-in-the-loop). - Fix prompts, models, and versions; maintain validation records (IQ/OQ/PQ) and audit logs. Prioritize defense against False Negatives (missed violations). - Avoid self-generation and self-verification; conduct review in a separate pass. **Key references** - Ministry of Health, Labour and Welfare, "Standards for Proper Advertising of Drugs, etc." (notice from the Director, Office of Pharmaceutical Safety, Narcotics Division) - Pharmaceutical and Medical Device Act (PMDA Act), Articles 66, 68, and 68-2 - Japan Pharmaceutical Manufacturers Association (JPMA), "Promotion Code for Prescription Drugs" - ICH/PIC/S GxP and Computerized System Validation (CSV) guidelines - FDA, "Artificial Intelligence in Drug & Biological Product Development" (2025 draft guidance)

## Applying Generative AI (LLMs) to Pharmaceutical Materials Review ### Benefits - **Faster review**: Automates consistency checks against package inserts and approval information, cutting review workload by up to 40–60% (McKinsey 2023 estimate) - **Consistency**: Reduces variation among reviewers and applies uniform criteria for Articles 66 and 68 of the Pharmaceutical and Medical Device Act - **Knowledge retention**: Vector search over past violation patterns enables early detection of similar issues ### Risks - **Hallucination**: Misclassifying off-label indications or dosage errors as "correct" - **Unsupported citations**: Generating nonexistent trial data or references (most acute in configurations without RAG) - **Accountability gap**: Inability to explain AI-derived findings to regulators (conflicts with EU AI Act Article 13 transparency requirements) - **Training data bias**: Models trained on outdated package inserts or pre-revision guidelines do not conform to current regulations ### Implementation considerations 1. **RAG is mandatory**: Ground responses in primary sources by referencing the internal regulatory database and package inserts in real time 2. **Human-in-the-loop**: Final approval rests with regulatory affairs staff; AI functions as "supplementary opinion" 3. **Audit logs**: All decision rationales stored in traceable form (GMP Annex 11 compliant) 4. **Validation**: Quantify False Negative rate against known violation cases before deployment --- ### Key references - FDA *Discussion Paper: Artificial Intelligence in Drug Development* (2023) - EU AI Act (Regulation 2024/1689), Article 13 (Transparency obligations) - McKinsey & Company, *Generative AI in Life Sciences* (2023) - Ministry of Health, Labour and Welfare, revised guidelines on software as medical devices (2023) - Mak K-K. et al., "Artificial intelligence in drug development," *Nature Reviews Drug Discovery* 18: 463–464 (2019)

## Regulatory Intent and Operation of Articles 66–68 of the Pharmaceutical and Medical Device Act (Prohibition of Misleading Advertising, etc.) **Statutory Structure** - **Article 66** (Misleading advertising, etc.) — Prohibits advertising, description, or dissemination of false or exaggerated statements — whether explicit or implicit — regarding the name, manufacturing method, efficacy, effectiveness, or performance of drugs and medical devices. Applies to all persons (not limited to pharmaceutical companies). Endorsements by physicians and other professionals, and documents suggesting abortion or obscenity, are also prohibited. - **Article 67** (Restrictions on advertising of drugs for specified diseases) — Restricts general-public advertising of drugs for diseases requiring physician supervision, such as cancer, as specified by Cabinet Order. - **Article 68** (Prohibition of advertising unapproved drugs, etc.) — Prohibits advertising the efficacy, effectiveness, etc. of drugs or medical devices before they have received approval or certification (prohibition of pre-approval advertising). **Regulatory Intent** The persuasive power of advertising stimulates demand and may lead to improper use and harm to public health. The goal is to ensure truthfulness and appropriateness of information and to protect the life and health of the public. Restrictions on freedom of expression are justified as the "minimum necessary for public health." **Operational Rules** Specific criteria are provided by the **Standards for Proper Advertising of Drugs, etc.** (established in 1980, revised multiple times; notice from the Director of the Office of Pharmaceutical Safety, Narcotics Division, MHLW), which prohibit superlative claims about efficacy or effectiveness, guarantees of safety, and disparagement of competitors. In addition to administrative guidance, the **surcharge system** introduced in the 2018 amendment (enforced 2021) under Article 75-5-2 (4.5% of sales during the violation period) applies. Obligations regarding the provision of proper use information are separately stipulated under Article 68-2 et seq. **Key references** - Pharmaceutical and Medical Device Act, Articles 66–68 - MHLW, "Standards for Proper Advertising of Drugs, etc." (first edition 1980, last revised 2017; director-level notice) - MHLW, "Interpretation and Notes on the Standards for Proper Advertising of Drugs, etc." - 2018 amendment to the Pharmaceutical and Medical Device Act (surcharge system, enforced 2021) - JPMA, "Promotion Code for Prescription Drugs" (Note: unapproved advertising = Article 68; misleading advertising = Article 66. These are separate provisions.)

## Articles 66–68 of the Pharmaceutical and Medical Device Act: Intent and Operation of the Prohibition on Misleading Advertising **Regulatory Intent** False or exaggerated information about drugs distorts consumers' independent judgment and causes harm through inappropriate use. The legislative purpose is to maintain public health and ensure proper use. **Role of Each Provision** | Article | Prohibited conduct | Persons covered | |------|---------|------| | 66 | False/exaggerated advertising (false efficacy claims, implied abortion, etc.) | Any person | | 67 | Restrictions on drug advertising for specified diseases (cancer, diabetes, etc.; delegated to ministerial ordinance) | Any person | | 68 | Prohibition on advertising unapproved products | Any person | **Key operational points** - Three requirements for "advertising" to be established: ① consumer solicitation, ② specificity, ③ recognizability (1998 MHLW notice) - Violating Article 66 carries a penalty of up to two years imprisonment or a fine of up to 2 million yen (the 2021 amendment also introduced a surcharge of 4.5% of sales) - Article 68 may apply to the publication of clinical trial results for unapproved products — an important practical consideration - Director-level notices (Yakuseikamaraha) from the Office of Pharmaceutical Safety, Narcotics Division continuously update specific criteria --- **Key references** - MHLW Pharmaceutical Affairs Bureau Director notice, "Standards for Proper Advertising of Drugs, etc." (Yakuhatsu No. 1339, 1980; revised 2017) - MHLW Office of Pharmaceutical Safety, Narcotics Division Director notice, "Interpretation and Notes on the Standards for Proper Advertising of Drugs, etc." (Yakuseikamaraha 0929 No. 5, 2017) - Editorial Committee, *Pharmaceutical Law Handbook* (Yakuji Nippo, latest edition) - Mitsushi Miyajima, "Legal Structure of Pharmaceutical Advertising Regulation," *Pharmaceutical Law Studies*, Vol. 37 (2012) - PMDA, "Q&A on Drug Advertising Regulation" (updated 2022)

## Regulatory Intent of the Guidelines on Sales Information Activities (Hantei-G) and Their Impact on MR Activities **Background and Intent** The full title is "Guidelines on Sales Information Activities for Prescription Drugs." Issued on September 25, 2018 as a notice from the Director-General, Pharmaceutical Safety and Environmental Health Bureau, MHLW, and effective April 2019. The immediate trigger was the social criticism sparked by the Novartis Valsartan (Diovan) clinical research data manipulation scandal (discovered 2013) — representative of exaggerated and improper promotion that deviated from the evidence. The key feature is that it extends the restrictions on misleading advertising and off-label promotion under Articles 66–68 of the Pharmaceutical and Medical Device Act to all "sales information activities," including oral explanations and e-detailing. **Core Regulatory Requirements** ① Thorough grounding in scientific and objective evidence; ② prohibition of acts that emphasize efficacy alone while concealing adverse safety information; ③ as a rule, prohibition of providing off-label information with explicitly stated exceptions; ④ record creation and retention. The guidelines cover not only MRs but also MSLs and promotional materials, and require companies to establish an internal review and oversight structure (sales information oversight department, designated responsible persons, annual evaluation). **Impact on MR Activities** All contacts — oral, slides, and email — became subject to audit, making routine work of pre-approval review of company-produced materials and documentation of explanatory content. Together with the Promotion Code, the role of MRs has been redefined from "sales promotion" to provision of appropriate use information, with emphasis on the quality and transparency of information. **Key references** - MHLW Pharmaceutical Safety and Environmental Health Bureau Director-General notice, "Guidelines on Sales Information Activities for Prescription Drugs" (Yakusei No. 0925 No. 1, 2018) - MHLW, "Q&A on the Guidelines on Sales Information Activities" (2019) - Pharmaceutical and Medical Device Act, Articles 66 and 68 - JPMA, "JPMA Promotion Code" - MHLW Expert Committee Report on the Valsartan (Diovan) Case (2014)

## Regulatory Intent of Hantei-G and Its Impact on MR Activities **Regulatory Intent** Issued in September 2018 as a notice from the Director, Office of Pharmaceutical Safety, Narcotics Division, MHLW, these guidelines were developed to correct the reality that pharmaceutical companies' drug information provision had blurred the boundary between "advertising" and "medical information provision," leading to promotion of off-label use and inflated impressions of efficacy. They function as a supplementary interpretive guide to Articles 66 (misleading advertising) and 68 (unapproved advertising) of the Pharmaceutical and Medical Device Act, and their most distinctive feature is the explicit statement of three principles: accuracy, fairness, and neutrality. **Key Impact on MR Activities** - Company approval process now mandatory for providing information outside approved indications in the package insert - Strengthened obligation for self-inspection of comparative advertising and exaggerated claims - Documentation retention and internal review obligations for lectures and presentations - Explicit retention period for information provision records (at least five years) - Oral references to unapproved indications clearly brought within the scope of regulation After the 2019 implementation, companies were compelled to strengthen the authority of materials review departments and redesign their pre-approval workflows. --- **Key references** - MHLW Office of Pharmaceutical Safety, Narcotics Division Director notice, "Guidelines on Sales Information Activities for Prescription Drugs" (Yakuseikamaraha 0924 No. 5, September 2018) - JPMA, "Self-Inspection Checklist for Compliance with the Sales Information Activities Guidelines" (2019) - MHLW, "Standards for Proper Advertising of Drugs, etc." (Showa 55, Yakuhatsu No. 1339; revised 2017) - Pharmaceutical and Medical Device Act, Articles 66 and 68 - Japan Medical Association / JPMA, "Promotion Code for Prescription Drugs" (revised 2021)

## From the Nuremberg Code to the Declaration of Helsinki: Where We Stand Today The Nuremberg Code (1947) emerged from the Doctors' Trial (Nuremberg Military Tribunal, 1946–47) and declared at the outset that "the voluntary consent of the human subject is absolutely essential." It was the first codification of research ethics, but its norms were set by a court, not a medical body. The medical profession internalized these norms through the Declaration of Helsinki (World Medical Association, adopted 1964). It built on the consent principle and extended it to include surrogate consent for subjects lacking decision-making capacity and prior review of research protocols. The 1975 Tokyo revision institutionalized prior review by independent ethics committees (later IRBs), and through multiple subsequent revisions — culminating in Brazil (2013) — it clarified restrictions on placebo use, guarantees of post-trial access, and the primacy of participant protection over scientific and social benefit. In parallel, in the United States the exposure of the Tuskegee syphilis study (1932–72) led to the Belmont Report (1979), which articulated the three principles of "respect for persons, beneficence, and justice," forming the theoretical foundation of today's IRB and informed consent requirements. At the international level, the CIOMS guidelines (latest 2016) and ICH-GCP (1996) govern operational standards. The current endpoint is a shift from (1) voluntary consent alone to (2) a comprehensive framework encompassing independent review, protection of vulnerable populations, conflict of interest management, and post-trial access — and the establishment of the principle that participant welfare always takes precedence over scientific and social benefit. **Key references** - The Nuremberg Code (1947) - World Medical Association, *Declaration of Helsinki* (1964; latest revision 2013) - National Commission, *The Belmont Report* (1979) - CIOMS, *International Ethical Guidelines for Health-related Research Involving Humans* (2016) - ICH, *Guideline for Good Clinical Practice E6* (1996; R2 2016)

## Current State of Medical Research Ethics: From Nuremberg to Helsinki **The Nuremberg Code (1947)** was born as the ten principles embedded in the verdict of the Doctors' Trial. Its core proposition — "the voluntary consent of the human subject is absolutely essential" — is the origin of informed consent (IC). **The Declaration of Helsinki (1964, WMA)** restructured this as a physicians' professional ethic. It brought therapeutic research involving patients within its scope and introduced the institutional framework combining IC with prior review by an ethics committee. Three subsequent major revisions produced three key transitions: 1. **1975 Tokyo revision**: Mandatory independent ethics review committees (IRB/IEC) 2. **2000 Edinburgh revision**: Use of placebo-controlled trials in principle restricted to situations where no proven treatment exists 3. **2013 Fortaleza revision**: Obligations for post-trial access to participants and transparency in registration and publication of results The current endpoint is four pillars: IC + independent review + balance of social value and scientific validity + protection of vulnerable populations. This aligns with the three principles — respect for autonomy, beneficence, and justice — formalized in the Belmont Report (1979), and has been implemented as a regulatory requirement through ICH-GCP (1996/E6 Revision R2). --- **Key references** - Trials of War Criminals before the Nuremberg Military Tribunals, Vol. II (1949) — contains original Nuremberg Code text - World Medical Association. *Declaration of Helsinki*, 2013 (Fortaleza revision) - National Commission for the Protection of Human Subjects. *The Belmont Report* (1979) - ICH Harmonised Guideline E6(R2): Good Clinical Practice (2016) - Emanuel EJ, Wendler D, Grady C. "What Makes Clinical Research Ethical?" *JAMA* 283(20):2701–2711, 2000

Pharmaceutical company ethics is discussed as the structural tension between "the logic of profit-seeking as a for-profit enterprise" and "the responsibility to handle medicine as a public good." **Where the tension lies**: Drugs are directly tied to health and life, yet their development requires enormous investment (on the order of $1 billion per new drug) and monopoly recoupment through patents, embedding conflicts of interest (COI) in pricing, access, and information provision. The late-1950s thalidomide scandal and the 2004 Vioxx (rofecoxib) cardiovascular risk concealment are cited as canonical examples of corporate judgment taking precedence over patient safety. **Mainstream regulatory and ethical frameworks**: Current thinking moves toward "self-regulation is insufficient; institutional correction of information asymmetry is needed." (1) In research ethics, the Declaration of Helsinki (1964, WMA) and ICH-GCP require protection of participants and scientific validity. (2) In sales information, the U.S. Physician Payments Sunshine Act (2010) and Japan's Transparency Guidelines (2011, JPMA) require disclosure of financial transfers to physicians, making "management and disclosure" of COI the ethical core. (3) IFPMA/JPMA codes of practice prohibit misleading advertising. **Current issues**: Among Beauchamp & Childress's four principles (autonomy, non-maleficence, beneficence, justice), "justice = equitable access" has become the focal point in recent years, with high drug prices, global health disparities, and data transparency (selective publication of clinical trials, AllTrials campaign) at the center. The mainstream view does not reject the profit motive itself, but treats "controlled commerce" — subordinating it to medical purposes through transparency, third-party oversight, and regulation — as the ethical endpoint. **Key references** - Beauchamp & Childress, *Principles of Biomedical Ethics* (8th ed., 2019) - World Medical Association, Declaration of Helsinki (1964; latest revision 2013) - Marcia Angell, *The Truth About the Drug Companies* (2004) - US Physician Payments Sunshine Act (2010) / JPMA, "Transparency Guidelines for the Relationship between Corporate Activities and Medical Institutions" (2011) - Lo & Field (eds.), *Conflict of Interest in Medical Research, Education, and Practice* (IOM, 2009)

## Pharmaceutical Company Ethics: The Tension between Profit and Medicine **The core structural tension** is that "maximizing shareholder value" and "maximizing patient care" are institutionally opposed. The U.S. Bayh-Dole Act of 1980 accelerated the patenting of university inventions by companies, making conflicts of interest between academia and industry the norm. **Three layers of key ethical issues:** 1. **Access disparities**: Price manipulation of HIV drugs, insulin, etc. (2001 South Africa litigation, in which WIPO TRIPS provisions were contested) 2. **Evidence manipulation**: Selective trial publication (unpublished paroxetine data, 2004 GlaxoSmithKline settlement) 3. **Marketing-first culture**: Prescribing influence through KOL speaker fees and rebates (PhRMA Code 2002 revision strengthened self-regulation) **Current mainstream regulatory framework**: Pillars include ICH E6(R2) GCP (revised 2016), the FDA Sunshine Act (effective 2013) for transparency obligations, and EMA independence guidelines (2017). In Japan, the JPMA Code and Transparency Guidelines on the relationship between corporate activities and medical institutions (2011) serve comparable functions. Academic consensus acknowledges the "limits of self-regulation without structural reform" and positions mandatory independent trial registration (ClinicalTrials.gov, mandated 2007) and results disclosure obligations as the minimum institutional safeguard. --- **Key references** - Angell, M. (2004). *The Truth About the Drug Companies*. Random House. - Lexchin, J. et al. (2003). Pharmaceutical industry sponsorship and research outcome. *BMJ*, 326, 1167. - Rodwin, M.A. (2012). Conflicts of interest, institutional corruption, and pharma. *Journal of Law, Medicine & Ethics*, 40(3), 511–522. - Turner, E.H. et al. (2008). Selective publication of antidepressant trials. *NEJM*, 358, 252–260. - Japan Pharmaceutical Manufacturers Association (2011). Transparency Guidelines for the Relationship between Corporate Activities and Medical Institutions.

Pharmaceutical company CEOs bear the dual responsibility of maximizing shareholder value while ensuring patient safety and public health. The balancing mechanisms are **Enterprise Risk Management (ERM)** and **compliance-driven governance**. **ERM essentials**: The COSO ERM framework (2004; revised 2017 to integrate with strategy and performance) and ISO 31000 (2009/2018) are de facto standards. CEOs view risk not as a problem for individual departments but as a portfolio tied to strategic objectives. Pharmaceutical-specific risks span clinical development failure probabilities, drug pricing and reimbursement, manufacturing quality (GMP), pharmacovigilance (post-market safety), and supply chain disruption. The Vioxx recall (Merck, 2004) and J&J Tylenol crisis (1982) continue to be cited as examples of safety neglect threatening corporate survival. **Compliance governance**: In the U.S., operations are governed by the Anti-Kickback Statute, the Foreign Corrupt Practices Act (FCPA), and **Corporate Integrity Agreements (CIAs)** under the False Claims Act. The $3 billion settlement by a major pharmaceutical company in 2012 marked a turning point. Benchmarks include the OIG's seven elements of an effective compliance program, the Sarbanes-Oxley Act (2002) on internal controls, and the U.S. Department of Justice's "Evaluation of Corporate Compliance Programs" (updated 2020). The core is **tone at the top** — CEOs themselves communicate ethical values, link compensation to safety and quality metrics, and institutionalize a culture that protects whistleblowers. A modern requirement is countering normalcy bias and groupthink through institutional design. **Key references** - COSO, *Enterprise Risk Management—Integrating with Strategy and Performance* (2017) - ISO 31000:2018, *Risk management — Guidelines* - U.S. DOJ, *Evaluation of Corporate Compliance Programs* (updated 2020) - OIG, *Compliance Program Guidance for Pharmaceutical Manufacturers* (2003) - U.S. Sarbanes-Oxley Act (2002)

## Decision-Making Structure of Pharmaceutical CEOs: ERM and Compliance Governance **Entrenchment of the Three Lines of Defense Model** Modern pharmaceutical CEOs ground their approach in the "Three Lines of Defense." They clearly demarcate roles among business units (first line), risk management/legal (second line), and internal audit (third line), and serve as the integrated owner of that structure, accountable to the Board. The IIA's 2020 revision of the Three Lines Model integrated an "advisory function" into the second line, promoting a shift from reactive to preventive approaches. **Pharmaceutical-Specific Issues in ERM** The pharmaceutical quality system defined in ICH Q10 (2008) directly links manufacturing risk to corporate strategy. The FDA's Quality Management Maturity (QMM) program (launched 2021) rates companies' quality culture, establishing the practice of CEOs reporting quality KPIs to the Board of Directors on a par with financial metrics. **Making Compliance Effective** HHS-OIG Corporate Integrity Agreements (CIAs) impose personal certification obligations on CEOs at companies with prior violations (e.g., a major pharmaceutical company's $3B settlement in 2012). Recent trends include "speak-up culture," quantitative KPIs for internal reporting, and transparency disclosure in the ESG context. In Japan, PDCA documentation in response to the 2023 amendment to the Pharmaceutical and Medical Device Act is required. --- **Key references** - IIA, *The Three Lines Model* (2020) - ICH Q10, *Pharmaceutical Quality System* (2008, Step 4) - FDA, *Quality Management Maturity Program* — Guidance for Industry (2021) - HHS-OIG, *Compliance Program Guidance for Pharmaceutical Manufacturers* (2003; 2023 Updated General Guidance) - Eisenberg, T. & Miller, G.P., "The English versus the American Rule on Attorney Fees," *Cornell Law Review* — [cited as reference; ERM litigation cost analysis]

Life-related industries (pharmaceuticals, healthcare, food — industries directly tied to human life and health) are treated distinctively in corporate governance theory as "credence goods" industries. The central issue is **information asymmetry**. As Kenneth Arrow argued in his 1963 classic in health economics, consumers (patients) cannot verify the safety and efficacy of products or services either before or after use. Lacking the expertise to assess whether something works or is harmless, market pricing mechanisms alone cannot guarantee quality, and supplementation through professional norms, regulation, and corporate self-governance (compliance) is a prerequisite. Because verification is impossible, the industry **accumulates trust as quasi-capital**. Long-term trust is built through the accumulation of clinical trial data, track records of GxP (GMP/GCP/GVP, etc.) compliance, histories of dialogue with regulatory agencies (Japan's PMDA, the U.S. FDA, the EU's EMA), and the integrity of adverse event reporting (pharmacovigilance). As the thalidomide tragedy (1957–62) — which prompted the 1962 U.S. Kefauver-Harris amendments and regulatory tightening worldwide — illustrates, the regulatory framework itself has been built in response to past collapses of trust. The core of this industry's distinctiveness is the **asymmetric time structure of trust**: slow to accumulate, fast to lose. As the Valsartan (Diovan) clinical research misconduct (2013, Novartis), the Takata airbag problem, and various international data falsification cases demonstrate, a single cover-up or falsification can instantly destroy decades of accumulated credibility. The behavioral economics concept of loss aversion and the asymmetry captured by the saying "trust arrives on foot and leaves on horseback" manifests here as a risk to corporate survival. The mainstream governance view therefore emphasizes **fiduciary responsibility to stakeholders (patients and society)** over shareholder value maximization, and the organizational embedding of an "integrity" culture that goes beyond formal compliance. Transparent disclosure, an independent quality assurance function, and internal controls that surface inconvenient information are the structural defenses against the speed at which trust is lost. **Key references** - Arrow, K. J. "Uncertainty and the Welfare Economics of Medical Care" (*American Economic Review*, 1963) - Akerlof, G. "The Market for Lemons" (*QJE*, 1970) - OECD, *Corporate Governance Principles* (revised 2023) - Freeman, R. E. *Strategic Management: A Stakeholder Approach* (1984) - MHLW/PMDA, related ministerial notifications on GVP (Good Vigilance Practice) for drugs

## Distinctive Characteristics of Life-Related Industries: Mainstream Governance and Ethics Theory **Information Asymmetry** Since Freeman's (1984) stakeholder theory, the pharmaceutical and medical device industries have been characterized as having a structural asymmetry in which "patients cannot independently assess the safety of products." The agency problem identified by Jensen & Meckling (1976) is multiplied across three parties — physicians, companies, and patients — requiring regulatory authorities (FDA, EMA, PMDA) to perform an institutional supplementary function by mandating disclosure. **Accumulation of Trust** Building trust capital requires long-term accumulation of clinical trial data and transparent disclosure in post-market safety monitoring (PMS/PVMS). In reputation economics (Kreps 1990), honest behavior constitutes an equilibrium under repeated games, but life-related industries differ from general industries in that "a single failure eliminates future opportunities for repetition." **Speed of Loss** Fombrun & Shanley's (1990) reputation research explicitly addresses the asymmetry of trust loss. In pharmaceuticals, the Vioxx case (Merck, 2004) is the canonical example: ten years of accumulated trust translated directly into a 27% loss in market capitalization on the day litigation was announced. In Japan, Article 68-2 of the Pharmaceutical and Medical Device Act regulates the obligation to provide information, institutionalizing the dual risk of social and legal sanctions for violations. --- **Key references** - Freeman, R.E. (1984). *Strategic Management: A Stakeholder Approach*. Pitman. - Jensen, M.C. & Meckling, W.H. (1976). Theory of the firm. *Journal of Financial Economics*, 3(4), 305–360. - Kreps, D.M. (1990). Corporate culture and economic theory. In *Perspectives on Positive Political Economy*. Cambridge UP. - Fombrun, C. & Shanley, M. (1990). What's in a name? *Academy of Management Journal*, 33(2), 233–258. - Graham, D.J. et al. (2005). Risk of acute myocardial infarction and sudden cardiac death with rofecoxib. *Lancet*, 365, 475–481.

Freud, Jung, and Adler diverged from the early-twentieth-century Viennese psychoanalytic movement and each left behind a distinctly different framework for "self-understanding." **Freud** (1856–1939) placed the unconscious at the center in *The Interpretation of Dreams* (1900), defining self-understanding as the work of making repressed drives, childhood experiences, and defense mechanisms conscious. The structural model of id/ego/superego (1923) is its skeleton, and free association and transference analysis are its methods. **Jung** (1875–1961) broke with Freud in 1913 and posited a collective unconscious common to humanity, along with archetypes (shadow, anima/animus), beneath the personal unconscious. Self-understanding meant the process of "individuation" — integrating conscious and unconscious — and his typology of introversion/extraversion became the source of later personality classifications. **Adler** (1870–1937) established Individual Psychology and viewed human beings as indivisible wholes. Key concepts are the inferiority feeling and its compensation, the striving for superiority, the lifestyle, and the community feeling (Gemeinschaftsgefühl). Self-understanding is a teleological reading of "purpose (why one behaves as one does)" rather than past causes. **Influence on modern psychology**: Jung's typology flows into the MBTI; Adler's teleology and encouragement feed into cognitive behavioral therapy, positive psychology, and Beck/Ellis's cognitive theories. Freud's unconscious hypothesis is criticized for lack of empirical evidence but survives clinically through attachment theory and psychodynamic therapy. All three share the premise that "people do not fully know themselves" and place self-exploration at the heart of treatment — the foundation of modern counseling. **Key references** - S. Freud, *The Interpretation of Dreams* (1900); *The Ego and the Id* (1923) - C. G. Jung, *Psychological Types* (1921); *The Relations Between the Ego and the Unconscious* - A. Adler, *Understanding Human Nature* (1927); *What Life Could Mean to You* - H. Ellenberger, *The Discovery of the Unconscious* (1970) — intellectual-historical positioning of all three - E. Hergenhahn & T. Henley, *An Introduction to the History of Psychology* (approx. 580 characters)

## The Three Great Psychologists' Frameworks for "Self-Understanding" and Their Influence on the Present **Freud (1856–1939)** proposed the three-layer structure of unconscious/preconscious/conscious and the second topography of id/ego/superego. He defined self-understanding as "the process of making the contents of the repressed unconscious conscious." The concepts of transference and resistance in psychoanalysis are inherited by modern dynamic psychotherapy (object relations theory, self psychology). **Jung (1875–1961)** added the "collective unconscious" and archetypes to the personal unconscious. He conceived of self-realization (individuation) as "the process of integrating the persona, shadow, and anima/animus to arrive at the whole Self." This perspective continues to influence narrative therapy and depth psychological career theory. **Adler (1870–1937)** prioritized "teleology" over the unconscious, placing the compensation of inferiority feelings and "community feeling (Gemeinschaftsgefühl)" at the axis of self-understanding. This connects to cognitive behavioral therapy (especially rational emotive therapy) and well-being research in positive psychology. The shared legacy of all three is "questioning the meaning of symptoms," and even within today's DSM-diagnosis-centered clinical practice they are practically reintegrated through ACT, schema therapy, and psychodynamic therapy. --- **Key references** - Freud, S. (1923). *Das Ich und das Es*. Internationaler Psychoanalytischer Verlag. - Jung, C. G. (1939). *The Integration of the Personality*. Farrar & Rinehart. - Adler, A. (1927). *Menschenkenntnis*. Hirzel. - Ellenberger, H. F. (1970). *The Discovery of the Unconscious*. Basic Books. - Norcross, J. C., & Goldfried, M. R. (Eds.). (2005). *Handbook of Psychotherapy Integration* (2nd ed.). Oxford University Press.

The Dunning-Kruger effect was reported by Justin Kruger and David Dunning in 1999 (*Journal of Personality and Social Psychology*) as the tendency for low-ability individuals to overestimate their own performance while highly skilled individuals slightly underestimate theirs. At its core is a "metacognitive blind spot": the **dual-burden** hypothesis that the knowledge required to recognize one's own errors is identical to the knowledge required to solve the task correctly. The effect is most pronounced in domains such as grammar and logic, where the ability to perform correctly and the ability to evaluate one's performance depend on the same skill. Current mainstream understanding, however, has substantially revised the interpretation of this effect. First, critics (Krueger & Mueller, 2002) argue that statistical artifacts — the better-than-average effect, ceiling/floor effects in measurement, and regression to the mean — produce the apparent gradient. Second, Nuhfer et al. (2016–2017) showed with real data that self-assessment error is close to uncorrelated with ability, emphasizing the contribution of measurement artifacts over pure cognitive bias. Third, Gignac & Zajenkowski (2020) pointed out that similar patterns can arise from random noise alone. In sum, while the descriptive tendency of low-ability individuals to overestimate themselves reproduces robustly, the classical interpretation attributing the cause solely to a metacognitive deficit is now seen as limited. Treating it as a phenomenon compounded by statistical artifacts is the current standard position in cognitive psychology. **Key references** - Kruger, J. & Dunning, D. (1999). "Unskilled and Unaware of It." *J. Pers. Soc. Psychol.*, 77(6), 1121–1134. - Krueger, J. & Mueller, R. A. (2002). "Unskilled, Unaware, or Both?" *J. Pers. Soc. Psychol.*, 82(2), 180–188. - Nuhfer, E. et al. (2017). "How Random Noise and a Graphical Convention Subverted Behavioral Scientists' Explanations." *Numeracy*, 10(1). - Gignac, G. E. & Zajenkowski, M. (2020). "The Dunning-Kruger effect is (mostly) a statistical artefact." *Intelligence*, 80, 101449.

## The Dunning-Kruger Effect and Metacognitive Blind Spots Originating in experiments published by David Dunning and Justin Kruger at Cornell University in 1999. It refers to the phenomenon whereby people with lower ability tend to overestimate themselves, but **the root cause is a lack of metacognitive ability** — the structural paradox that recognizing one's own incompetence requires precisely the skill that is absent. Current mainstream understanding has revised the "pure overconfidence bias" hypothesis. Re-analyses by Krajc & Ortmann (2008) and Ecker et al. indicated that portions of the original data can be explained as **statistical artifacts (regression-to-the-mean effects)**. Gignac & Zajenkowski (2020) confirmed the effect in a larger sample while reporting that the magnitude is small. Current consensus: - The effect is real but **has been over-interpreted** - The self-underestimation of high-ability individuals ("the second curve") is equally important - Domain-specificity is strong; it cannot be reduced to a general "fools lack self-awareness" thesis Research on metacognitive blind spots (Pronin et al., 2002, "bias blind spots") also connects here, and training has been shown to improve the ability to view one's own cognitive limitations from a distance. --- **Key references** - Kruger, J. & Dunning, D. (1999). Unskilled and unaware of it. *Journal of Personality and Social Psychology*, 77(6), 1121–1134. - Gignac, G. E. & Zajenkowski, M. (2020). The Dunning-Kruger effect is (mostly) a statistical artefact. *Intelligence*, 80, 101380. - Krajc, M. & Ortmann, A. (2008). Are the unskilled really that unaware? *Journal of Economic Psychology*, 29(3), 311–321. - Pronin, E., Lin, D. Y., & Ross, L. (2002). The bias blind spot. *Personality and Social Psychology Bulletin*, 28(3), 369–381. - Dunning, D. (2011). The Dunning–Kruger effect. *Advances in Experimental Social Psychology*, 44, 247–296.

The concept of "self-esteem," widely promoted in education and clinical practice since Rosenberg's (1965) scale, reached a turning point with the meta-analysis by Baumeister, Campbell, Krueger, and Vohs (2003, *Psychological Science in the Public Interest*). They concluded that evidence supporting the causal claim that high self-esteem "produces" academic achievement, occupational success, or violence suppression was scant, that correlations were weak, and often that success raises self-esteem — not the reverse. They also criticized the 1980–90s American "self-esteem movement" (e.g., the California Task Force to Promote Self-Esteem) for boosting self-esteem without substantive basis. They further noted (Bushman & Baumeister 1998) that fragile high self-esteem and narcissism are linked to aggression. Against this backdrop, related concepts were re-evaluated. Bandura's self-efficacy (1977/1997) is "confidence in one's ability to perform a specific task" — domain-specific and consistently more predictive of performance than global self-evaluation, i.e., self-esteem. Neff's self-compassion (2003) consists of three elements — self-kindness, common humanity, and mindfulness — and does not make self-evaluation contingent on social comparison or success, compensating for the shortcomings of conditional, unstable self-esteem. Research shows that self-compassion more stably contributes to reduced depression and anxiety and is uncorrelated with narcissism, whereas self-esteem correlates with both. Overall, the focus has shifted from promoting vague self-affirmation to action-based efficacy and self-acceptance. Key references - Baumeister, R. F., Campbell, J. D., Krueger, J. I., & Vohs, K. D. (2003). *Psychological Science in the Public Interest*, 4(1). - Bandura, A. (1997). *Self-Efficacy: The Exercise of Control*. Freeman. - Neff, K. D. (2003). *Self and Identity*, 2(2, 3). - Bushman, B. J., & Baumeister, R. F. (1998). *Journal of Personality and Social Psychology*, 75(1). - Rosenberg, M. (1965). *Society and the Adolescent Self-Image*. Princeton Univ. Press.

Baumeister et al. (2003, *Psychological Science in the Public Interest*) concluded that high self-esteem is a correlate rather than a cause of academic, interpersonal, and health outcomes, and that its violence-suppression effect is also unsupported. This stripped the "self-esteem education" boom of its empirical basis and surfaced the problem of conflation with narcissism. **Comparison with alternative constructs** - **Self-efficacy (Bandura, 1977–)**: Task-specific belief in one's ability to perform. Meta-analyses (Stajkovic & Luthans, 1998) show high predictive validity for performance — more directly tied to behavior change than comprehensive "self-evaluation." - **Self-compassion (Neff, 2003–)**: Replacing self-criticism with compassion — cognitive and emotional regulation. While high self-esteem produces comparison-dependence and self-defensiveness, self-compassion strengthens resilience after failure and is uncorrelated with narcissism (Neff & Vonk, 2009). Current consensus: "Do not make high self-esteem itself a goal." Self-efficacy has independent intervention rationale as a predictor of motivation and behavior; self-compassion has independent intervention rationale as a protective factor for mental health. --- **Key references** - Baumeister, R.F. et al. (2003). Does high self-esteem cause better performance? *Psychological Science in the Public Interest, 4*(1), 1–44. - Bandura, A. (1997). *Self-efficacy: The exercise of control*. Freeman. - Neff, K.D. (2003). Self-compassion: An alternative conceptualization of a healthy attitude toward oneself. *Self and Identity, 2*(2), 85–101. - Neff, K.D., & Vonk, R. (2009). Self-compassion versus global self-esteem. *Journal of Personality, 77*(1), 23–50. - Stajkovic, A.D., & Luthans, F. (1998). Self-efficacy and work-related performance: A meta-analysis. *Psychological Bulletin, 124*(2), 240–261.

## Intellectual Lineage of Self-Criticism The first to structuralize self-critical tendencies was **Sigmund Freud**. In *The Ego and the Id* (1923), the **superego (Über-Ich)** he proposed is an agency that internalizes parental and social prohibitions, monitors and punishes the ego, and is the source of guilt. He emphasized that aggression, rather than being directed outward, is turned against the self. **Karen Horney** then formalized the **"tyranny of the should"** in *Neurosis and Human Growth* (1950). She argued that an inner imperative to reach an idealized self-image ("I should be like this") drives people relentlessly, and that the gap between this ideal and the real self generates self-hatred (self-hate). Advancing the cognitive turn in behavior was **Albert Ellis**, who founded Rational Emotive Behavior Therapy (REBT) around 1955. He operationally handled the insight of Horney through the concept of "musturbation," positing that **irrational beliefs** centered on "must/should" generate emotional disturbance. **Aaron T. Beck** established **cognitive therapy** in the 1960s and systematized **cognitive distortions** in depression — all-or-nothing thinking, overgeneralization, should statements, self-referencing, etc. — making them measurable and modifiable as automatic thoughts. More recently, **Brené Brown** defined **shame** through qualitative research (grounded theory, from the 2000s) as "the sense that one, as a person, is defective," distinguishing it from guilt over actions. She repositioned self-criticism in the context of relationships and vulnerability. This is a lineage in which an internalized agency gradually shifted from psychodynamics → inner imperatives → beliefs → cognition → emotion into a **measurable, intervable object**. ### Key references - Freud, S. (1923). *Das Ich und das Es* (*The Ego and the Id*). - Horney, K. (1950). *Neurosis and Human Growth*. - Ellis, A. (1962). *Reason and Emotion in Psychotherapy*. - Beck, A. T. (1979). *Cognitive Therapy of Depression*. - Brown, B. (2012). *Daring Greatly*.

Freud (*The Ego and the Id*, 1923) defined the **superego** and showed the mechanism by which internalized parental and social prohibitions punish the ego, laying the foundation for self-criticism. Horney (*Neurosis and Human Growth*, 1950) conceptualized the **"tyranny of the should."** She argued that the gap between the ideal self and the real self generates a cycle of shame and contempt, extending the superego concept into a relational context. Ellis (1955, founder of Rational Emotive Behavior Therapy) identified **irrational beliefs** — rigid propositions such as "If I am not perfect, I am worthless" — and made cognitive restructuring the therapeutic core. Beck (1960s, cognitive therapy) empirically classified **automatic thoughts and cognitive distortions** (all-or-nothing thinking, overgeneralization, catastrophizing) and operationally defined the self-critical mechanism of depression. Brown (grounded theory research from 2006 onward) sharply distinguished **shame** from guilt. She formulated shame as a totalizing evaluation of "the self as defective" — with disconnection from the desire to belong as its core. --- **Key references** - Freud, S. (1923). *Das Ich und das Es*. Internationaler Psychoanalytischer Verlag. - Horney, K. (1950). *Neurosis and Human Growth*. Norton. - Ellis, A. (1962). *Reason and Emotion in Psychotherapy*. Lyle Stuart. - Beck, A. T. (1979). *Cognitive Therapy of Depression*. Guilford Press. - Brown, B. (2006). Shame resilience theory. *Journal of Clinical Social Work*, 34(1), 43–62.

The Buddhist Middle Way is the practical principle taught by the Buddha, who rejected both asceticism and indulgence as extremes, and was philosophically deepened by Nāgārjuna in his *Mūlamadhyamakakārikā* (c. 2nd century CE). He equated "emptiness" (śūnyatā) — the thesis that all things lack independent inherent existence (svabhāva) — with "dependent origination" (pratītyasamutpāda, the mutually dependent arising of phenomena), and took a position that leaves behind both the views of existence and nonexistence. This stance contains the attitude of observing phenomena "as they are" without fixing judgments. This non-substantialist, decentering mode of observation flowed indirectly into modern clinical mindfulness. Jon Kabat-Zinn founded MBSR (Mindfulness-Based Stress Reduction) at the University of Massachusetts in 1979, medicalizing the Zen and Vipassana training of "directing attention to the present without evaluation." ACT (Acceptance and Commitment Therapy; Steven Hayes, 1980s–90s; grounded in Relational Frame Theory) places "cognitive defusion" — viewing thoughts as events rather than facts — and the "observing self" at its core. These structurally resonate with the logic of emptiness and dependent origination in that they relax attachment to thoughts (treating them as inherently existent). Both therapies should be noted, however, to have secularized and reconstructed their approaches through functional contextualism and empirical research, rather than directly inheriting Buddhist philosophy. Key references - Nāgārjuna, *Mūlamadhyamakakārikā* (c. 2nd century CE); Garfield English translation, 1995 - Kabat-Zinn, J. *Full Catastrophe Living* (1990) - Hayes, S.C., Strosahl, K., Wilson, K.G. *Acceptance and Commitment Therapy* (1999; 2nd ed. 2012) - Gethin, R. *The Foundations of Buddhism* (1998)

## Lineage from Buddhist Philosophy to MBSR and ACT **The Middle Way and Deidentification** Nāgārjuna's (2nd–3rd century) emptiness (śūnyatā) logicized the "negation of a fixed, essential self," and dependent origination (pratītyasamutpāda) logicized the "mutually dependent arising of phenomena." These two axes connect to modern psychotherapy. **MBSR (1979, Kabat-Zinn)** Jon Kabat-Zinn translated Zen and Vipassana into a medical context. The practice of "directing attention to the present without judgment" structurally corresponds to the Middle Way's attitude of "leaving behind attachment to extreme judgments." The perspective of dependent origination — "placing symptoms within their context" — functions to alleviate catastrophic thinking. **ACT (Hayes, 1986–2004)** Acceptance and Commitment Therapy places "cognitive defusion (thought defusion)" at its core. This is functionally isomorphic to Nāgārjuna's logic that "linguistic concepts are empty," and aligns with the stance of not grasping thoughts as "inherently real truths." Hayes explicitly mentions the correspondence with Buddhist philosophy in his papers. **Common Structure** Both therapies take the Middle Way position that "suffering (dukkha) is transformed through observation rather than avoidance." The view that the self should not be treated as a fixed entity (non-self/emptiness) provides the philosophical basis for the concept of psychological flexibility. --- **Key references** - Kabat-Zinn, J. (1990). *Full Catastrophe Living*. Delacorte Press. - Hayes, S. C., Strosahl, K. D., & Wilson, K. G. (1999). *Acceptance and Commitment Therapy*. Guilford Press. - Garfield, J. L. (1995). *The Fundamental Wisdom of the Middle Way* (Nāgārjuna's Mūlamadhyamakakārikā). Oxford University Press. - Germer, C. K., Siegel, R. D., & Fulton, P. R. (Eds.). (2005). *Mindfulness and Psychotherapy*. Guilford Press. - Williams, J. M. G., & Kabat-Zinn, J. (2011). Mindfulness: Diverse perspectives on its meaning, origins, and multiple applications. *Clinical Psychology & Psychotherapy*, 18(6), 533–544.

Adlerian Individual Psychology was founded by Alfred Adler (1870–1937) after his break with Freud. **Separation of tasks** (Aufgabentrennung) refers to the attitude of distinguishing "my tasks" from "other people's tasks" by asking who bears the consequences of a given matter — not intruding into others' tasks and not allowing intrusion into one's own. It is inseparable from the denial of the need for approval and is described as a practical principle for reducing interpersonal distress. **Community feeling** (Gemeinschaftsgefühl/social interest) is the sense of viewing others as allies and gaining a sense of belonging through "contribution," and is both the ultimate goal of Adlerian psychology and an indicator of mental health. The two are in a state of tension: separating from others with boundaries while connecting through contribution — a reciprocating structure. In Japan, philosopher Ichiro Kishimi and writer Fumitake Koga rendered these concepts accessible in an accessible dialogue format in *The Courage to Be Disliked* (Diamond, 2013), which became a bestseller. The background was approval fatigue, interpersonal stress in the social-media age, and the appeal of teleology as a counterpoint to trauma determinism. It was dramatized by Fuji Television in 2017, and the sequel *The Courage to Be Happy* (2016) was also published. Academic criticisms have also been raised, including selective interpretation of the original texts, proximity to personal responsibility discourse, and weakness of the evidence base. **Key references** - Kishimi, I. & Koga, F. *The Courage to Be Disliked*. Diamond, 2013 - A. Adler, *The Psychology of the Life Sense* (orig. 1933) - Kishimi, I. *Introduction to Adlerian Psychology*. KK Best Sellers, 1999 - H. L. Ansbacher & R. R. Ansbacher (eds.), *The Individual Psychology of Alfred Adler*, 1956 - Noda, T. *Speaking of Adlerian Psychology*. Sogensha

## Re-evaluation of Adlerian Psychology: Separation of Tasks and Community Feeling Alfred Adler (1870–1937)'s **Individual Psychology** was one of the streams of depth psychology alongside Freud and Jung, but had lost relative prominence in the second half of the twentieth century. **Separation of tasks** (Aufgabentrennung) is a practical concept that resolves interpersonal friction by asking "whose task is this?" The principle of non-interference — neither intruding into others' tasks nor allowing others to intrude on one's own — has strong affinity with the modern concept of "boundaries." **Community feeling** (Gemeinschaftsgefühl) is the sense of an individual being connected to society and the universe as a whole — the core concept that Adler positioned as an indicator of mental health. Connected to contribution motivation that transcends self-interest, it also interfaces with "purpose-oriented" research in positive psychology. In 2013, *The Courage to Be Disliked*, an introductory dialogue book by philosopher Ichiro Kishimi and writer Fumitake Koga, became a bestseller (over 3 million copies cumulatively). It explained Adlerian psychology's "denial of the need for approval" and "teleology" in accessible terms, popularizing Adlerian psychology in Japan. Including the 2019 sequel *The Courage to Be Happy*, applications in organizational development, coaching, and education expanded rapidly. --- **Key references** - Adler, A. (1927). *Menschenkenntnis*. S. Hirzel. - Dreikurs, R. (1950). *Fundamentals of Adlerian Psychology*. Greenberg. - Kishimi, I. & Koga, F. (2013). *The Courage to Be Disliked*. Diamond. - Mosak, H. H., & Maniacci, M. (1999). *A Primer of Adlerian Psychology*. Brunner/Mazel. - Suzuki, Y. (2016). "Re-examination of the community feeling concept in Adlerian psychology." *Individual Psychology Research*, 22(1), 1–14.

## 1937 Sulfanilamide Elixir Disaster — Regulatory and Institutional Lessons **Overview**: In 1937, S.E. Massengill Company in the U.S. used **diethylene glycol** (an antifreeze component with lethal nephrotoxicity) as a solvent to create a sweet liquid formulation of the antibacterial drug sulfanilamide. Marketed as "Elixir Sulfanilamide," it killed approximately **105 people**, mainly children. Under the applicable federal law at the time (the Pure Food and Drug Act of 1906), **pre-market safety testing was not required**, and the only legal basis on which the FDA could intervene was a **misbranding violation** — the term "elixir" implies an alcoholic preparation, yet the product contained no alcohol. The chemist Harold Watkins subsequently took his own life. **Institutional lessons and consequences**: This disaster directly prompted the passage of the **Federal Food, Drug, and Cosmetic (FD&C) Act of 1938**. Its core was the introduction of a pre-market approval system: manufacturers must **submit an NDA (New Drug Application) to the FDA demonstrating safety**, and may market the product if no objection is raised within a specified period. It marks the turning point from post-market enforcement to **placing the burden of demonstrating safety on manufacturers before marketing**. (The efficacy requirement would not come until the **Kefauver-Harris amendments** prompted by the thalidomide disaster in 1962.) In current mainstream understanding, this case is the canonical example of **"disaster-driven regulation"** and the starting point of toxicology testing institutionalization and the modern pharmaceutical regulatory framework. **Key references** - Wax PM. "Elixirs, Diluents, and the Passage of the 1938 Federal Food, Drug and Cosmetic Act." *Annals of Internal Medicine*, 1995. - Ballentine C. "Sulfanilamide Disaster." *FDA Consumer*, 1981. - U.S. Federal Food, Drug, and Cosmetic Act of 1938 (primary source). - Geiling EMK, Cannon PR. "Pathologic Effects of Elixir of Sulfanilamide (Diethylene Glycol) Poisoning." *JAMA*, 1938. - Hilts PJ. *Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation*. 2003.

## 1937 Sulfanilamide Elixir Disaster: Regulatory and Institutional Lessons **Overview** S.E. Massengill Company's chief chemist Harold Watkins dissolved sulfanilamide in diethylene glycol (DEG). The product was shipped without any pre-market toxicity testing, killing at least 107 people. **Institutional Turning Point** The 1906 Pure Food and Drug Act **did not require pre-market proof of efficacy or safety**. The only basis on which the FDA could act was the trivial provision of false labeling (the product contained no alcohol despite the name "elixir"). This disaster directly prompted the **1938 Federal Food, Drug, and Cosmetic (FD&C) Act**. Three core reforms: 1. **Mandatory pre-market safety review** — creation of the New Drug Application (NDA) system 2. **Legal authority to inspect factories** — granting the FDA authority to enter manufacturing facilities 3. **Legal basis for the prescription drug category** — precursor to the requirement of use under physician supervision **Modern Significance** Establishment of the principle that "the burden of proving non-harm rests with the manufacturer." It became the cornerstone of the later 1962 Kefauver-Harris amendments (mandating proof of efficacy, following the thalidomide disaster). --- **Key references** - Ballentine, C. (1981). "Taste of Raspberries, Taste of Death." *FDA Consumer*, June 1981. - Jackson, C.O. (1970). *Food and Drug Legislation in the New Deal*. Princeton University Press. - Wax, P.M. (1995). "Elixirs, Diluents, and the Passage of the 1938 Federal Food, Drug and Cosmetic Act." *Annals of Internal Medicine*, 122(6), 456–461. - Carpenter, D. (2010). *Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA*. Princeton University Press. - Young, J.H. (1967). *The Medical Messiahs*. Princeton University Press.

## Thalidomide Disaster (1957–1962): Regulatory Lessons and the Role of Frances Kelsey **Overview** Thalidomide was developed by Chemie Grünenthal in West Germany and marketed in 1957 as a sedative and anti-nausea drug for morning sickness. Its teratogenicity led to approximately 10,000 children worldwide being born with limb reduction defects (amelia/phocomelia). In 1961, W. Lenz (Germany) and W. McBride (Australia) warned of the causal relationship and the drug was recalled in multiple countries. **Regulatory Lessons** 1. **Shifting the burden of pre-approval safety proof to companies** — In the U.S., the 1962 Kefauver-Harris amendments mandated proof of efficacy, adequate and well-controlled studies, informed consent, and adverse event reporting. 2. Institutionalization of **post-market surveillance (pharmacovigilance)** and the starting point of the WHO International Drug Monitoring Programme (1968). 3. Standardization of **fetal exposure and teratogenicity testing**. **Frances Kelsey's Role** A Canadian-born pharmacologist and physician. In 1960, as an FDA reviewer handling Richardson-Merrell's application (trade name Kevadon), she withheld approval six times, citing insufficient safety data on peripheral neuropathy and other issues, and continued to resist despite industry pressure — preventing large-scale entry of the drug into the U.S. market. She received the President's Award for Distinguished Federal Civilian Service from President Kennedy in 1962. Her judgment provided political momentum for the Kefauver-Harris amendments and became a symbol of the FDA's strengthened scientific review authority. ### Key references - Kefauver-Harris Amendments (Drug Amendments of 1962), Public Law 87-781 - Lenz W. "A short history of thalidomide embryopathy." *Teratology* (1988) - McBride WG. *Lancet* (1961) — first report of teratogenicity - FDA, "Frances Oldham Kelsey: Medical Reviewer Famous for Averting a Public Health Tragedy" (FDA History Office) - Stephens T, Brynner R. *Dark Remedy: The Impact of Thalidomide* (2001)

## The Thalidomide Disaster and Regulatory Lessons **Overview**: In 1957, Grünenthal in West Germany marketed it as a sleeping drug and anti-nausea agent for morning sickness. Approximately 10,000 children with phocomelia were born, mainly in Europe and Japan. In Japan, sales continued after the European recall in 1961, and the damage expanded until 1963. **Frances Kelsey's Role**: As an FDA reviewer, she received the application from Richardson-Merrell in 1960. Citing inadequate animal study data, reports of neurotoxicity, and concerns about teratogenicity risk, she repeatedly refused approval despite industry pressure. When the European harm became clear in 1962, large-scale damage in the U.S. was averted. She received the Federal Medal for Distinguished Civilian Service from President Kennedy the same year. **Institutional Lessons**: - **Kefauver-Harris Amendments (1962)**: Legally mandated proof of efficacy and pre-trial informed consent requirement, becoming the prototype for modern GCP (Good Clinical Practice) - **Mandatory teratogenicity testing**: Non-clinical reproductive toxicity evaluation incorporated as an approval requirement - **Strengthened post-market surveillance**: Institutional development of spontaneous reporting systems (pharmacovigilance) accelerated in multiple countries --- **Key references** - Bren L. "Frances Oldham Kelsey: FDA Medical Reviewer Leaves Her Mark on History." *FDA Consumer*, 2001. - Fintel B, et al. "The Thalidomide Tragedy: Lessons for Drug Safety and Regulation." *Helix*, Northwestern University, 2009. - Kim JH, Scialli AR. "Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease." *Toxicological Sciences*, 122(1), 2011. - Daemmrich A. "A Tale of Two Experts: Thalidomide and Political Engagement in the United States and West Germany." *Social History of Medicine*, 15(1), 2002.

The SMON case involved Subacute Myelo-Optico-Neuropathy (SMON), which became prevalent in Japan from around 1955, affecting approximately 10,000 patients. In 1970, Tadao Tsubaki of Niigata University epidemiologically identified the intestinal drug clioquinol (chiniofon) as the cause, and the Ministry of Health and Welfare halted sales the same year. The subsequent SMON litigation and 1979 settlement became a turning point in pharmaceutical administration. In current regulatory science, SMON is understood — alongside thalidomide (around 1962) — as the direct trigger for institutionalizing Japan's post-market safety measures. Specifically: (1) the 1979 revision of the Pharmaceutical Affairs Act creating the "Drug Side-Effect Relief Fund" (later integrated into the Pharmaceuticals and Medical Devices Agency, PMDA); (2) statutory codification of re-examination and re-evaluation systems; and (3) clarification of companies' adverse event reporting obligations and emergency authority to halt sales. The philosophy of PMS (post-market surveillance, later GVP/GPSP, pharmacovigilance) — actively monitoring and correcting previously unknown adverse effects even after approval — is rooted in the SMON lesson that "drug harm can first become apparent only after post-approval, long-term, large-scale exposure." The fact that national regulatory responsibility was acknowledged also provided grounds for institutionally embedding administrative safety surveillance obligations. **Key references** - Tsubaki T. "SMON and Clioquinol." *Journal of the Japanese Society of Internal Medicine* (1970s) - MHLW, *Summary Report of the SMON Research Group* - 1979 Pharmaceutical Affairs Act revision documents; PMDA explanation of the Drug Side-Effect Relief System - Takano, T. *Drug Harm in Japan* - Sato N et al. "History of Drug Harm and Pharmacovigilance" (*Pharmacoepidemiology*) (Note: Bibliographic details of some references should be verified against primary sources.)

## The SMON Case and Its Impact on Japan's PMS System **Overview** From around 1955, abdominal symptoms and neuropathy became prevalent. In 1970, Tadao Tsubaki et al. established the causal link with clioquinol (an intestinal drug), which was banned the same year. Approximately 11,000 victims, many with vision loss and lower-limb paralysis. **Institutional Turning Points** SMON, as a typical case of "drug harm that became apparent only post-market," directly drove the following: 1. **1979 Pharmaceutical Affairs Act revision** — Legally codified the re-examination system (re-examination and re-evaluation system) at 10-year intervals for manufacturing approvals. Enabling provisions were established for ongoing verification of efficacy and safety even after approval. 2. **Strengthening of adverse event reporting obligations** — Institutionalization of spontaneous reporting obligations (ICSR) from companies to MHLW accelerated. 3. **Drug Harm Victim Relief System (1979)** — Enactment of the Drug Side-Effect Relief Fund Act. Became a leading model for no-fault compensation. 4. **GVP Ministerial Ordinance (2004)** — Through subsequent Pharmaceutical Affairs Act revisions, systematized as the Good Vigilance Practice (GVP) standard for post-approval safety management. Requires companies to establish safety management oversight departments and designated safety managers. **Current Academic Positioning** In the context of regulatory science, SMON is cited as evidence that "an institutional vacuum in post-approval surveillance produced large-scale drug harm," illustrating the *necessity of both passive surveillance (spontaneous reporting) and active surveillance (research studies)* in PMS design. --- **Key references** - Tsubaki T et al. "Virological and Epidemiological Studies of SMON." *Clinical Neurology*, 1970 - MHLW, "Act Partially Amending the Pharmaceutical Affairs Act," 1979 (establishing the re-examination system) - SMON Litigation Tokyo District Court Judgment, 1978 (finding liability on the part of the state, Takeda Pharmaceutical, etc.) - Japan Pharmaceutical Manufacturers Association, *History of Post-Market Drug Safety Measures*, 2010 - Iijima M (ed.), *Research on Drug Harm* (Nagoya University Press, 1985)

The HIV-contaminated blood products case involved approximately 1,800 hemophilia patients infected with HIV through non-heat-treated blood clotting factor preparations in the 1980s, with many deaths. From current medical ethics and administrative responsibility theory, the following structural failures are cited as lessons. First, the absence of the precautionary principle. By 1983, the United States was moving to switch to heat-treated preparations and issuing risk warnings, but the Ministry of Health and Welfare and the research group (headed by Dr. Abe Takeshi, Chair of the AIDS Research Group) continued to distribute non-heat-treated preparations, citing insufficient scientific evidence. The stance of "not acting until causation is confirmed" expanded the harm. This is the failure to apply the precautionary principle — prioritizing harm avoidance under uncertainty. Second, unchecked conflicts of interest. The pharmaceutical companies (Green Cross and others) were entangled with the regulatory side and researchers through personnel and financial ties, compromising the independence of regulation. Green Cross had amakudari (descent from heaven) officials from the former Ministry of Health and Welfare. Third, information asymmetry and violation of patient autonomy. Infection risks were not disclosed to patients, and informed consent failed to function. Fourth, diffusion of responsibility. Responsibility was dispersed among pharmaceutical companies, the state (failure to exercise regulatory authority), and physicians — producing a structure in which nobody bore ultimate responsibility. Following the 1996 settlement and the formal acknowledgment of state responsibility by then-Minister of Health Naoto Kan, and through the subsequent blood products hepatitis case, the theory of administrative responsibility for "regulatory inaction as illegal" became established. The lessons are embodied in the establishment of an independent safety regulatory agency (now PMDA), institutionalization of the precautionary principle, conflict of interest management, and mandatory drug harm education. **Key references** - Gunji A. *Safety as an Illusion: Learning from the AIDS Controversy* (2015) - Muto K et al. Papers on bioethics in drug harm research (Journal of the Japan Association for Medical Law) - MHLW, "Report of the Study Group on Education to Learn from Drug Harm and Prevent Recurrence" (2010) - Supreme Court / Tokyo / Osaka HIV Litigation Settlement Confirmation Documents (1996) - Kuroyanagi T. *The HIV-Contaminated Blood Products Case and the Responsibility of Medicine and Administration*. Houritsu Jiho (Note: Some references indicate representative scholars/public materials; precise bibliographic details should be verified from primary sources.)

## Structural Failures and Lessons of the HIV-Contaminated Blood Products Case **Facts**: In the 1980s, approximately 1,800 hemophilia patients infected with HIV through non-heat-treated concentrated blood clotting factor preparations; over 400 deaths. The Ministry of Health and Welfare, pharmaceutical companies (Green Cross, etc.), and medical associations formed a "community of interests." **Three Layers of Structural Failure** 1. **Intentional blocking of information**: Even after the U.S. FDA approved heat-treated preparations in 1983, a research group led by Professor Abe Takeshi of Teikyo University delayed approval under the pretext of "insufficient domestic data." Pharmaceutical companies' market protection overlapped with the established interests of the academic community. 2. **Regulatory capture by administration**: The Pharmaceutical Affairs Bureau of the Ministry of Health and Welfare was a destination for amakudari from the industry and lacked an independent safety evaluation function. It was only when then-Minister Naoto Kan publicly released official documents in 1996 stating that "the infection of HIV patients was known and concealed" that administrative responsibility was first made visible. 3. **Absence of informed consent**: Information on infection risks to patients was systematically suppressed, and the ethical norms for protecting research subjects (Nuremberg Code, Declaration of Helsinki) had not taken root in domestic clinical settings. **Current mainstream understanding**: The four points of ① institutional management of conflicts of interest, ② an independent risk evaluation agency (PMDA, established 2004), ③ legally mandated precautionary principle of "suspend use in case of doubt," and ④ obligations to preserve and disclose administrative documents — are regarded as the direct institutional responses. The criminal judgment (Dr. Abe: guilty verdict finalized 2008) was incorporated into administrative responsibility theory as "harm through inaction." --- **Key references** - Kurihara C. "The HIV-Contaminated Blood Products Case and Medical Ethics." *Bioethics*, vol. 7, 1997 - Masuyama Y. *Structure of Drug Harm*. Iwanami Shoten, 2006 - Report on Strengthening Drug Safety Measures, MHLW, 2002 (on the background to establishing PMDA) - Eric Feldman, "Blood Justice: Courts, Conflict, and Compensation in Japan, France, and the United States," *Law & Society Review*, 2000 - Japan Association for Bioethics (ed.), *Encyclopedia of Bioethics*. Taiyo Shuppan, 2010 (entry on "Drug Harm")

## State Information Management Responsibility in the Blood Products Hepatitis Case Fibrinogen preparations (manufactured by Green Cross) were approved in 1964 and widely used for hemostasis at childbirth and other occasions; despite going through non-heat-treated and heat-treated processing, the risk of hepatitis C virus contamination remained, and an estimated 10,000 or more people were infected. The core of the state's (Ministry of Health and Welfare's) information management responsibility lies in the following points. First, after the U.S. FDA withdrew approval for fibrinogen preparations in 1977, Japan continued use without restricting indications. Second, in 2002 the Ministry of Health, Labour and Welfare obtained the existence of a list of blood product recipients (the so-called "list of 418") from the successor to Green Cross, yet left infected individuals without notification. This "failure to inform individuals of information that would have enabled them to know the fact of administration" is treated in the mainstream of medical policy history as the core of the state's responsibility. Following district court judgments in Osaka, Fukuoka, and other cities in 2006, the Special Measures Act for Relief of Blood Products Hepatitis Victims (private member legislation) was enacted in 2008, and Prime Minister Yasuo Fukuda apologized, acknowledging state responsibility. Subsequently, review and examination committees were established to summarize the structural deficiencies in "the duty to transmit information in pharmaceutical administration" and harm expansion prevention. The mainstream understanding positions the delay in approval and recall decisions, plus the failure to convey information held to the affected parties, as the essence of "information management responsibility." **Key references** - Committee for Verification of the Blood Products Hepatitis Case and an Ideal Model for Pharmaceutical Administration for Prevention of Recurrence, *Final Proposal* (2010) - Special Measures Act for Relief of Blood Products Hepatitis Victims (2008, Law No. 2 of Heisei 20) - MHLW, "Report on Fibrinogen Preparations and Factor IX Preparations" (2002 and 2007) - Uchida H. *Medical Law and the Rights of Patients and Medical Professionals* (Misuzu Shobo, 2021) - National Federation of Blood Products Hepatitis Plaintiffs and Defense Counsel (eds.), *History of the Blood Products Hepatitis Trial* (Nihon Hyoronsha, 2012)

## State Information Management Responsibility in the Blood Products Hepatitis Case In the 1980s, approximately 10,000 people were infected with hepatitis C through fibrinogen preparations (Fibrinogen-HT, etc.) manufactured by Green Cross and others. **The core issue is the information management practice of "knowing yet doing nothing."** The Ministry of Health and Welfare (at the time) became aware of FDA recommendations in 1987 and recognized the infection risk of the preparations. However, it ① did not issue a recall order, ② continued to allow use until fibrinogen was effectively prohibited during the O157 response in 1996, and ③ did not impose a preservation obligation for administration records (medical records) needed to identify infected individuals. Only when the Osaka District Court prosecutors seized internal Ministry of Health and Welfare documents in 2002 did "the structure of concealment" become visible. After the enactment of the Blood Products Hepatitis Relief Act and the government apology (Prime Minister Yasuo Fukuda) in 2008, subsequent policy history research (particularly the verification by the Drug Harm Ombudsman Council) characterizes the core problem as "the institutional fixing of information asymmetry." That is, the mainstream understanding is the structural deficiency in which three parties — the regulatory authority, pharmaceutical companies, and medical institutions — shared information on infection risks while lacking obligations to disclose to patients. --- **Key references** - Drug Harm Ombudsman Council, *Verification and Recommendations on the Blood Products Hepatitis Problem*, 2008 - Hanai T. "Policy History Verification of the Blood Products Hepatitis Case." *Social Policy*, vol. 4, no. 1, 2012 - Committee for Verification of the Blood Products Hepatitis Problem and an Ideal Model for Pharmaceutical Administration for Prevention of Recurrence, *Final Proposal*, 2010 - Inden R. "Drug Harm and State Responsibility — Legal Analysis of the Information Management Obligation." *Houritsu Jiho*, vol. 80, no. 3, 2008 - Leflar, R.B. "Informed Consent and Patients' Rights in Japan." *Houston Law Review*, 33(1), 1996